IN8bio (NASDAQ:INAB) Announces Quarterly Earnings Results

IN8bio (NASDAQ:INAB) announced its quarterly earnings results on Thursday. The company reported ($0.85) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.20) by $0.35, Zacks reports.

IN8bio Stock Performance

Shares of INAB stock traded down $0.11 during mid-day trading on Friday, reaching $1.55. The stock had a trading volume of 89,551 shares, compared to its average volume of 68,833. The firm has a market cap of $7.04 million, a PE ratio of -0.28 and a beta of 0.02. The company has a quick ratio of 7.03, a current ratio of 7.03 and a debt-to-equity ratio of 0.01. IN8bio has a one year low of $1.53 and a one year high of $12.53. The firm’s 50 day simple moving average is $2.09 and its 200 day simple moving average is $2.73.

Analysts Set New Price Targets

A number of equities analysts have recently commented on INAB shares. Mizuho set a $4.00 price target on shares of IN8bio in a research report on Monday, October 13th. Wall Street Zen raised IN8bio from a “sell” rating to a “hold” rating in a research report on Saturday, August 9th. Weiss Ratings reissued a “sell (e+)” rating on shares of IN8bio in a research report on Wednesday, October 8th. Finally, Zacks Research upgraded IN8bio from a “strong sell” rating to a “hold” rating in a research note on Tuesday, October 14th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $92.00.

IN8bio Company Profile

IN8bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM.